Samaan, Mark A.
Pavlidis, Polychronis
Papa, Sophie
Powell, Nick
Irving, Peter M.
Article History
First Online: 7 March 2018
Competing interests
: M.A.S. has received advisory fees from Hospira and lecture fees from Falk, Hospira, Janssen, MSD and Takeda. S.P. has received advisory fees from Amgen, MSD and Roche and lectures fees from Bristol–Myers Squibb and MSD. N.P. has received advisory fees from AbbVie, Allergan, Debiopharm International, Ferring and Vifor Pharma and lectures fees from Allergan, Falk, Janssen, Tillotts and Takeda. P.M.I. has received advisory fees from AbbVie, Genentech, Hospira, Janssen, MSD, Pharmacosmos, Samsung Bioepis, VH2, Vifor Pharma, Takeda, Topivert and Warner Chilcott, lecture fees from AbbVie, Falk, Ferring and Warner Chilcott and financial support for research from MSD and Takeda. P.P. declares no competing interests.